Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy

  • STATUS
    Recruiting
  • days left to enroll
    36
  • participants needed
    38
  • sponsor
    Algenis SpA
Updated on 24 March 2022

Summary

Proof-of-concept study to assess the effects of gonyautoxins (PSP NEURO SERUM) on safety and tactile sensitivity on patients with chemotherapy-induced peripheral neuropathy (CIPN). This is a multicenter, prospective proof-of-concept study in patients with solid tumors affected by CIPN. The study will be divided into two parts: Part 1 will assess the activity and tolerability of PSP NEURO SERUM and part 2 consists of a randomized cohort that will compare the activity of PSP NEURO SERUM vs placebo. Part 2 will depend on the results of part 1. If there are less than 8 responses in part 1, the study will be interrupted, and it will not be recommended to proceed with part 2. The detailed description of the study will be given only for part 1.

Description

A multicenter, prospective proof-of-concept study in patients with solid tumors who developed chemotherapy-induced peripheral neuropathy (CIPN) in upper limbs, equal or greater than grade 2, according to NCI-CTCAE version 5.0. Patients must have been treated with cytotoxic agents known to cause CIPN in neoadjuvant, adjuvant or palliative setting. The primary objective is to assess the effects of gonyautoxins (PSP NEURO SERUM) on tactile sensitivity and safety on patients with CIPN. The study will be divided into two parts, 1 and 2 and the investigational treatment will have a maximum duration of 4 weeks (28 days).

Part 1 is a two-stage (stage 1 and stage 2), two-cohort (C1 and C2), open-label study where 38 pts with G>2 CIPN secondary to taxanes (C1) and other anti-neoplastic drugs (C2) will receive PSP NEURO SERUM thrice a day for 28 days. Twelve patients will be evaluated in stage 1, expecting a 20% response (2/12) in each cohort to proceed to stage 2. Additional 7 patients will be recruited to stage, expecting 4/19 response in each cohort. If the number of responses is not met in a specific cohort, recruitment will be halted. The transition to the randomized part 2 will be determined by the efficacy in part 1 (stratified analysis of C1 and C2 or overall population).

The primary objective of Part 1 is to evaluate response of the tactile sensation as assessed by the Semmes-Weinstein monofilament test and to evaluate safety and toxicity (type, frequency, grade and causality of adverse effects) of PSP NEURO SERUM according to NCI-CTCAE v5.0.

The secondary objectives of Part 1 are to:

  1. Evaluate the improvement of overall neurological examination as assessed by the clinical version of Total Neuropathy Score (TNSc)
  2. Evaluate the improvement of manipulative dexterity and agility as assessed by the nine-hole pegboard test (NHPT).
  3. Evaluate the improvement in patient reported symptoms as assessed by the Patient Neuropathy Questionnaire (PNQ).
  4. Evaluate the improvement of quality of life by using the Portuguese version of the 30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC Quality of Life Questionnaire (QLQ-C30)) version.

The study procedures include:

  1. Screening Assessments
  2. Pre-treatment / Baseline Assessments (D1)
  3. D7 (± 1 day) - Assessments during Treatment
  4. D14 (± 1 day) - Assessments during Treatment
  5. D21 (± 1 day) - Assessments during Treatment
  6. End of Treatment (D28 + 3 days)
  7. Safety Follow-up Visit (30 ± 7 days from the last dose)

A patient will have responded to the CIPN in the study if there is a documented improvement of 30% (two sizes of evaluator) and / or normalization of the baseline pretreatment assessment as assessed by the Semmes-Weinstein monofilament test. A patient will have progressed CIPN in the study if there is a documented worsening in tactile sensation assessed by the Semmes-Weinstein monofilament test. Worse tactile sensation is defined as the change in one (1) size of the monofilament evaluator.

Details
Condition Chemotherapy-induced Peripheral Neuropathy
Treatment PSP NEURO SERUM
Clinical Study IdentifierNCT05052398
SponsorAlgenis SpA
Last Modified on24 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent
Age ≥18 years
Histological diagnosis of cancer (hematologic or solid tumors)
Treatment with chemotherapy in the neoadjuvant, adjuvant or metastatic setting
Peripheral sensory neuropathy grade 2 or higher on upper limbs as per NCI-CTCAE v5.0
Diagnosis of peripheral sensory neuropathy during treatment with chemotherapy or at least 2 weeks after the last infusion
Patients who completed treatment with chemotherapy over 2 weeks, but have chronic symptoms related to peripheral sensory neuropathy and no exclusion criteria can be included
Patients on neuropathic pain modulators will be allowed if on stable dose, if there were no dose changes in dosages in the last 2 weeks or if the use is for another reason
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2
Documented willingness to use an effective means of contraception while participating in the study
Skin of the hands and cuticles should be intact

Exclusion Criteria

Prior treatment with gonyautoxins or any small molecule neurotoxins
Female participants who are pregnant (positive urine pregnancy test), who have an infant they are breastfeeding, or intend to become pregnant within 3 months
History of sensory peripheral neuropathy attributed to any cause other than chemotherapy
Currently receiving chemotherapy or having had received chemotherapy in the past 2 weeks. Patients on systemic treatment that peripheral neuropathy is a commonly known side effect or received treatment in the last 2 weeks. Patients receiving systemic treatment, such as hormonal therapy or other agents where peripheral neuropathy is not a common side effect will be allowed
Patients with grade 2 CIPN with perceived improvement of symptoms
Changes in neuropathic pain modulators will not be allowed
Any other therapies for chemotherapy-induced peripheral neuropathy must be discontinued at least 2 weeks before the first dose of study drug
Hypersensitivity reaction to PSP Neuro serum
Patients with a known or suspected shellfish allergy
Patients receiving steroids or having received steroids in the past 2 weeks except for maximum of 10mg of prednisone or equivalent
No dermatologic lesions on hands and cuticles that might increase systemic exposure of the investigational medicinal product (IMP)
Distal muscle weakness and/or atrophy
History of alcoholism or regular (> 3 months) weekly alcohol intake of 168 g (21 units) for men and 112g (14units) for women. 1 unit = 10ml = 8g of pure alcohol
Clinically significant abnormalities of glucose metabolism as defined by any of the
following
Diagnosis of diabetes mellitus type I or II (irrespective of management) with preexisting symptoms related to peripheral neuropathy. Asymptomatic diabetic patients with well controlled glucose levels are allowed
Glycosylated hemoglobin (HbA1C) ≥8.0% at screening
Fasting serum glucose ≥ 160 mg/dL at screening. Fasting is defined as no caloric intake for at least 8 hours
Vitamin B12 deficiency defined as < 250 ng/mL
Phosphate levels above upper limit of normal (ULN)
ECG: corrected QT interval (QTc) (Fridericia Formula) ≥ 450ms
Positive Tinel and/or Phalen test
Participation in another clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry / randomization
Surgery, radiotherapy, or other anti-cancer therapy that in the investigators' opinion might interfere/ worsen symptoms or the evaluation of peripheral neuropathy within 2 weeks prior to trial entry /randomization
Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patients at high risk from treatment complications
Unresolved clinically significant toxicity from prior therapy except for alopecia
Inability to comply with study and follow-up procedures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note